mTOR vs AMPK: The Molecular Tug-of-War That Shapes Muscle and Longevity
A 2025 review maps how balancing mTOR-driven muscle growth against AMPK-driven cellular cleanup unlocks lasting metabolic health.
Resumen
Skeletal muscle mass depends on a dynamic balance between mTOR, which drives protein synthesis and hypertrophy, and AMPK, which promotes autophagy, mitochondrial biogenesis, and energy conservation. This 2025 narrative review synthesizes human trials and mechanistic studies to show that chronic mTOR hyperactivation raises risk for obesity, insulin resistance, neurodegeneration, and cancer, while strategic AMPK activation counterbalances those harms. Practical recommendations include ~1.6 g/kg/day total protein distributed evenly across meals, leucine-rich sources like whey for maximal mTOR stimulation, and periodic AMPK activation through aerobic training or intermittent fasting. Older adults benefit from higher per-meal doses (~0.40 g/kg) to overcome anabolic resistance. Neither pathway should dominate; the optimal state cycles between anabolic building and catabolic renewal.
Resumen detallado
Skeletal muscle is far more than a locomotor organ — it is a metabolic hub whose mass and quality predict longevity, insulin sensitivity, and resilience against chronic disease. Two opposing signaling nodes govern this tissue: mTOR, which integrates amino acid, growth factor, and mechanical signals to build muscle, and AMPK, which detects energy stress and triggers cellular housekeeping. Understanding how to strategically activate each pathway — and when — is increasingly recognized as a cornerstone of both performance medicine and healthy aging.
This narrative review by Jeong (Cureus, 2025) synthesizes literature from PubMed, Scopus, and Google Scholar through April 2025, covering human trials, meta-analyses, and mechanistic studies on mTOR/AMPK regulation, protein nutrition, exercise modality, and fasting protocols. The mechanistic sections detail how mTORC1 phosphorylates 4E-BP1 and S6K1 to unleash cap-dependent translation, boosts ribosomal RNA transcription, stimulates lipid and nucleotide biosynthesis via SREBP and CAD, and simultaneously suppresses autophagy by blocking ULK1, ATG13, UVRAG, and lysosomal transcription factors TFEB/TFE3. mTORC2 complements this by activating Akt for cell survival, glycogen synthesis, and actin cytoskeleton organization. AMPK opposes these effects by phosphorylating Raptor and upregulating TSC2 to shut down mTORC1, directly activating ULK1 to induce autophagy and mitophagy, stimulating mitochondrial biogenesis via PGC-1α, suppressing lipogenesis through ACC1/ACC2 and SREBP1 inhibition, and promoting glucose uptake via GLUT4 translocation.
On protein nutrition, meta-analyses confirm that ~1.6 g/kg/day maximizes muscle protein synthesis in resistance-trained individuals, with negligible added benefit beyond ~2.2 g/kg/day. Distributing intake evenly — approximately 0.25 g/kg per meal in younger adults and 0.40 g/kg per meal in older adults — enhances anabolic efficiency and helps overcome age-related anabolic resistance. Leucine-rich, rapidly absorbed proteins such as whey elicit the strongest mTOR response and are superior to slower sources like casein or plant proteins for acute muscle building, though total daily intake remains the dominant variable.
Exercise modality profoundly shapes pathway balance. Resistance training is the most potent physiological activator of mTORC1 in muscle. Concurrent training (combining endurance and resistance in the same session) can attenuate hypertrophy — an effect partially explained by AMPK activation from aerobic work blunting mTOR signaling — though this interference depends on session order, volume, intensity, and training status. Intermittent fasting and time-restricted eating reliably activate AMPK, improve insulin sensitivity, and support body composition remodeling without sacrificing muscle when protein targets are met.
Clinically, chronic mTOR hyperactivation is implicated in type 2 diabetes (via S6K1-mediated insulin receptor substrate phosphorylation), cancer cell proliferation, and neurodegenerative protein aggregation, whereas AMPK activators like metformin and exercise mitigate these risks. The review argues that longevity-oriented strategies should cycle between anabolic phases (resistance training, adequate protein) and catabolic renewal phases (fasting windows, aerobic exercise) rather than maximizing either pathway in isolation.
Hallazgos clave
- ~1.6 g/kg/day protein maximizes muscle protein synthesis in resistance trainers; benefits plateau beyond ~2.2 g/kg/day.
- Older adults need ~0.40 g/kg per meal vs ~0.25 g/kg in younger adults to overcome anabolic resistance.
- Leucine-rich whey protein elicits the strongest mTOR activation and acute muscle-building response.
- Concurrent endurance + resistance training can blunt hypertrophy via AMPK-mediated mTOR suppression.
- Intermittent fasting activates AMPK, promotes autophagy and mitochondrial biogenesis, and preserves muscle when protein needs are met.
Metodología
This is a narrative literature review drawing on PubMed, Scopus, and Google Scholar through April 2025, incorporating human RCTs, meta-analyses, and mechanistic animal/cell studies. No formal PRISMA protocol, predefined inclusion/exclusion criteria, or quantitative risk-of-bias assessment was applied, consistent with its narrative design.
Limitaciones del estudio
As a narrative review without systematic search protocols or risk-of-bias scoring, selection bias and overrepresentation of positive findings are possible. Mechanistic insights are largely extrapolated from rodent and cell models; human in-vivo pathway dynamics remain incompletely characterized. Individual variability in mTOR/AMPK responses based on genetics, training history, and disease state is not fully addressed.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte: